New Data Shows Qsymia Reduces Progression to Diabetes

New clinical data shows that patients receiving Qsymia (phentermine HCl/topiramate extended-release; Vivus, Inc.) capsules, in conjunction with lifestyle modifications, experienced significant weight loss along with markedly reduced progression to type 2 diabetes and improvements in multiple cardiometabolic disease risk factors, as published online in Diabetes Care.  

RELATED: Endocrine Disorders Resource Center

Study investigators conducted a subanalysis of SEQUEL, a Phase 3, randomized, placebo-controlled, double-blind study of overweight/obese subjects (BMI >27–<45kg/m2) with >2 comorbidities. They aimed to evaluate the effect of Qsymia treatment on progression to type 2 diabetes and/or cardiometabolic disease in patients with prediabetes and/or metabolic syndrome at baseline.

A total of 475 high-risk patients  were randomized to placebo, Qsymia 7.5mg/46mg, or Qsymia 15mg/92mg plus lifestyle modifications for 108 weeks. 

After 108 weeks, patients with prediabetes and/or metabolic syndrome in the placebo, Qsymia 7.5mg/46mg, and 15mg/92mg arms experienced mean percent weight loss of 2.5%, 10.9%, and 12.1%, respectively (P<0.0001). 

Also, the Qsymia 7.5mg/46mg and 15mg/92mg treatment arms were associated with reductions of 70.5% and 78.7%, respectively, in the annualized incidence rate of type 2 diabetes (P<0.05).

Qsymia is a combination of a sympathomimetic amine and antiepileptic indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30kg/m2 or ≥27kg/m2 in the presence of at least one weight related co-morbidity (eg, hypertension, type 2 diabetes, or dyslipidemia).

For more information call (888) 998-4887 or visit